4:19 PM
 | 
Jan 22, 2018
 |  BC Extra  |  Company News

Taiwan Liposome forms marketing JV with Jixi

Taiwan Liposome Co. Ltd. (TPEx:4152) said it entered into a joint venture with Jixi Biotechnology to promote and market its drugs more efficiently in China. Jixi will invest $20 million to purchase a partial stake in TLC Biopharmaceuticals (H.K.) Ltd., a Hong Kong subsidiary of Taiwan Liposome, through which Taiwan Liposome's...

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >